Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Borneol/cilostazol - NeuroDawn Pharmaceutical

Drug Profile

Borneol/cilostazol - NeuroDawn Pharmaceutical

Alternative Names: Cilostazol dexborneol - NeuroDawn Pharmaceutical; cilostazol/borneol - NeuroDawn Pharmaceutical; cilostazol/dexborneol - NeuroDawn Pharmaceuticals; d-borneol/cilostazol - NeuroDawn Pharmaceuticals; Y 6; Y-6 sublingual tablet

Latest Information Update: 22 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn
  • Class Anti-inflammatories; Antiplatelets; Antiseptics; Antispasmodics; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Quinolines; Small molecules; Terpenes; Tetrazoles; Traditional Chinese medicine; Vascular disorder therapies
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Stroke
  • Preclinical Cognition disorders

Most Recent Events

  • 14 Nov 2023 NeuroDawn Pharmaceuticals plans a phase II FUTURE trial for Stroke (In adults, In the elderly) (Sublingual, Tablet) in November 2023 (NCT06138834)
  • 04 Aug 2023 Chemical structure information added
  • 05 Jun 2023 Phase-II clinical trials in Stroke in China (Sublingual) (NCT05836766)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top